ClinicalTrials.gg
RecruitingNCT04790240COVIDUpdated Feb 19, 2025

Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

A Phase 1/2 interventional study of Inflammation (I) and Inflammation (II) in Covid19 Virus Infection, sponsored by All Natural Medicine Clinic, LLC. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by All Natural Medicine Clinic, LLC · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Planned enrollment
626th of 1,322
100 · median 92
Started
2025
with 45 others
Phase 1/2
62 of 1,860
4 open now
Primary completion
2026-12
later than 78 of 208 live
Registered
981st of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 626th largest by planned enrollment of the 1,322 interventional ones that give a count, is one of 46 that started in 2025, is one of 62 in phase 1/2, reaches primary completion later than 78 of the 208 other live ones, and was the 981st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and dependably defend the body against disease and illness.

When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back. When the medical herbs join the body, it can slow down the immune reaction. Medical herbs benefit the physical body; they protect the cells and organism structure and mediate the immune response, allowing the T cells to kill the virus (mutated or not) internally. Such success has been achieved by the All Natural Medicine Clinic during pre-clinical trials.

This clinical study's goal is to demonstrate that the immune system can be rebuilt and retrained, using natural medicine (i.e., medical herbs), to kill the virus without causing the immune storm, and to explore the mechanism by which these medical herbs, which have been used for thousands of years for healing, achieve results.

Read the detailed description

According to CDC data, as of January 30, 2021, 25,780,144 individuals residing in the United States had been infected by COVID-19 and 435,151 had died as a result of the disease. No drug has yet been identified that explicitly kills the COVID-19 virus. While various vaccines have been developed to prevent infection, the virus continues to mutate, and scientific research remains behind the virus trajectory.

The human immune system, when functioning properly, can prevent the body from succumbing to infections from external sources and from internal cell mutations, including the COVID-19 virus and cancer cells. That is, the defense system comes from nature. This clinical study proves that the immune system can respond to those antigens and kill them if the immune system is given a chance. However, the human immune system can become compromised through inflammation and subsequently unable to successfully prevent infection and cancer.

When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over-immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back.

Medical herbs can mediate the immunity disorder caused by infections, and mutated cells, including COVID-19 and its mutations. Our pre-clinical study found that the medical herbs inhibit the inflammation expression, reduce the chance of cytokine-storm, prevent deterioration, and reduce the mortality rate. In addition, the T cells can perform their job when the inflammation is under control. The virus and cancer cells belong to antigens that should be killed by natural killer (NK) cells and T cells. This clinical study aims not to provide drugs to kill the antigens, but rather to create the necessary conditions inside the human body to allow the immune system a chance to overcome the antigens. The clinic has used this treatment concept to successfully treat infected patients and cancer patients.

03

Conditions studied

  • Covid19 Virus Infection

Keywords

  • Medicinal Herbs
  • Virus
  • COVID-19
  • Coronavirus Disease 2019
  • Infections
  • Inflammation
  • Immunity
  • Metabolite
  • clots
  • thrombus
  • Viral Pneumonia
  • Fever
  • Cough
  • Chest congestion
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for inclusion in this study if any of the following criteria apply:

  • Individuals diagnosed with COVID-19 virus infection in the past 1-20 days must submit the proved metrics of COVID-19 virus marks positive during the registration;
  • The age of participants is between 10-70 years old;
  • The participants are received or not received conventional medication treatment, and continuing the treatment patients, could be enrolled in this clinical study;
  • This clinical study is not restricted to gender, age, sex, race, and nationality;
  • The participants must have reports of CBC, C3, C4, IgM, IgG, CD4/CD8, and lungs' images ready before the clinical study;
  • The Participants must repeat the evaluation experiment during and at the end of the clinical study.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • Individuals with a prior COVID-19 virus infection that no longer shows up from COVID-19 testing;
  • Children who are younger than 10-year-old, cannot control themselves to take the medical herbs on time;
  • Elders whose age beyond 70-year-old, with severe underline illness;
  • COVID-19 virus-infected patients who do not feel willing to take medical herbs;
  • Patients diagnosed with COVID-19 virus infection cannot consistently finish the treatment courses for a specific reason;
  • Patients diagnosed with COVID-19 virus infection but do not willing to share their information with the public;
  • Current or past participation within a specified timeframe in another clinical trial, as warranted by this intervention's administration;
  • Severe patients, when there have insufficient normal cells, can be adjusted, with pre-list diseases life-threatening.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Inflammation (I)

    1. Upper respiratory inflammation. 2. Fever. 3. Lower respiration inflammation.

    Dietary Supplement: Inflammation (I) · Drug: Standard of care

  • Active comparator
    Inflammation (II)

    Cough, chest pain

    Dietary Supplement: Inflammation (II) · Drug: Standard of care

  • Active comparator
    Inflammation (III)

    1. Metabolites 2. Clots

    Dietary Supplement: Inflammation (III) · Drug: Standard of care

Interventions

  • Dietary supplementInflammation (I)

    1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g 2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g 3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g

    Also known as: PurInf (I), PurInf (II), PurInf(III)

  • Dietary supplementInflammation (II)

    Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g

    Also known as: PurCo

  • Dietary supplementInflammation (III)

    1. Metabolites, abnormal fluids (PurPhl): Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g 2. Capillaries circulation disorder (PurClo): Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g

    Also known as: PurPhl, PurClo

  • DrugMedicationStudies of MedicationMedication pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.

    Also known as: Medications

06

What researchers measure

Primary outcomes

  1. recovering damaged organ

    comparing imagen of lungs

    Time frame: 3 weeks

  2. inhibiting inflammation

    comparing C-reactive protein (CRP)

    Time frame: 3 weeks

  3. preventing the antibody depositing on antigen

    measuring complement: C3, C4

    Time frame: 6 weeks

Secondary outcomes

  1. monitoring the antibody level

    measuring immunoglobulin M (IgM), immunoglobulin G (IgG)

    Time frame: 6 weeks

  2. correcting reversed immunity ratio

    measuring cluster of differentiation 4/cluster of differentiation 8 (CD4/CD8)

    Time frame: 6 weeks

  3. tracking the COVID virus marks

    SARS-CoV-2 Diagnostic (Molecular or Antigen) Testing

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wannzhu Hou Cellular Structure and its Function is the key for heeling Diseases, Certification and Registration number: TXu 1-938-144 July 30, 2014
  • Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol. 2014 Apr 16;5:171. doi: 10.3389/fimmu.2014.00171. eCollection 2014. PubMed 24795718 ↗
  • Zhou LK, Zhou Z, Jiang XM, Zheng Y, Chen X, Fu Z, Xiao G, Zhang CY, Zhang LK, Yi Y. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients. Cell Discov. 2020 Aug 5;6(1):54. doi: 10.1038/s41421-020-00197-3. eCollection 2020. No abstract available. PubMed 32802404 ↗
  • Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology. 1996 Apr;23(4):909-16. doi: 10.1053/jhep.1996.v23.ajhep0230909. No abstract available. PubMed 8666349 ↗
  • Zhou H, Sun L, Yang XL, Schimmel P. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature. 2013 Feb 7;494(7435):121-4. doi: 10.1038/nature11774. Epub 2012 Dec 23. PubMed 23263184 ↗
  • Dosch M, Gerber J, Jebbawi F, Beldi G. Mechanisms of ATP Release by Inflammatory Cells. Int J Mol Sci. 2018 Apr 18;19(4):1222. doi: 10.3390/ijms19041222. PubMed 29669994 ↗
  • Chen RJ, Jinn TR, Chen YC, Chung TY, Yang WH, Tzen JT. Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors. Acta Pharmacol Sin. 2011 Feb;32(2):141-51. doi: 10.1038/aps.2010.197. PubMed 21293466 ↗
  • Samuels N. Herbal remedies and anticoagulant therapy. Thromb Haemost. 2005 Jan;93(1):3-7. doi: 10.1160/TH04-05-0285. PubMed 15630483 ↗
  • Soni S, O'Dea KP, Tan YY, Cho K, Abe E, Romano R, Cui J, Ma D, Sarathchandra P, Wilson MR, Takata M. ATP redirects cytokine trafficking and promotes novel membrane TNF signaling via microvesicles. FASEB J. 2019 May;33(5):6442-6455. doi: 10.1096/fj.201802386R. Epub 2019 Feb 18. PubMed 30776316 ↗
  • Wanzhu Hou, et al. Treating Autoimmune disease with Chinses Medicine, Elsevier, 2011

Individual participant data

Plan to share: Yes — When we finish the project of the clinical study, we will share the individual participant's data (IPD) (but is not personal private to share) when the results in the publication

Supporting information: Study protocol

Time frame: The clinical study may start on February 1, 2021; the ending of the say maybe is December 31, 2022. The IPD sharing will begin after the publication in six months.

Access criteria: Viruses, including COVID-19, are highly likely to mutate. This capacity makes it particularly challenging to kill the virus with drugs. This clinical study designed two groups, both of they used the same drugs, but the treatment group pluses medical herbs, then both groups parallelly receive the treatment, then compare participants symptoms, blood test of immunity, the lungs imagine, and COVID-19 virus index, the difference in both group, analysis the symptoms and the mechanism.

Data sharing details ↗ · www.anmedicine.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 107 non-industry phase 1/2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 23 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Mar 10, 2021
StartActual
Jan 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
May 30, 2027
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04790240
Lead sponsor
All Natural Medicine Clinic, LLC
Responsible party
Wanzhu Hou (President, All Natural Medicine Clinic, LLC) — Principal investigator
First posted
Mar 10, 2021
Start date
Jan 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Wanzhu Hou, CMD, MD(CN)
Contact
info@anmedicine.com
1(301)770-4480
Wanzhu Hou, CMD,MD(CN)
principal investigator · All Natural Medicine Clinic, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion